Paolo Cotzia about the ESMO Tumor-Agnostic Classifier taxonomy
Paolo Cotzia shared a post on LinkedIn about recently published paper:
Authors: C B Westphalen, D Martins-Branco, J R Beal, C Cardone, N Coleman, A M Schram, S Halabi, S Michiels, C Yap, F André, F Bibeau, G Curigliano, E Garralda, S Kummar, R Kurzrock, S Limaye, S Loges, A Marabelle, C Marchió, J Mateo, J Rodon, T Spanic, G Pentheroudakis, V Subbiah.
”The proposed ESMO Tumor-Agnostic Classifier (ETAC) taxonomy to categorize precision therapeutics is a very interesting work.
The ESMO taxonomy is classifying molecularly guided treatment options based on the therapeutic effect obtained by targeting a driver molecular aberration across tumors and its modulation by tumor-specific biology.
Proposed categories are:
- tumor-agnostic (e.g. TRK inhibitors in tumors harboring NTRK gene fusions),
- tumor-modulated (e.g. PARP inhibitors in tumors harboring BRCA1/2 mutation/homologous recombination deficiency),
- tumor-restricted (e.g. PI3K inhibitors in PIK3CA-mutated breast cancer).
Further work is needed to define robust classification cut-offs to categorize precision therapeutics based on the interplay ‘driver molecular aberration’ with modulating ‘tumor-specific biology’.
This work has potential of optimizing drug development and accelerating patient access to effective targeted therapies.”
Source: Paolo Cotzia/LinkedIn
Paolo Cotzia is the Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare USA, as well as the Medical Director of Sonic Reference Laboratory. He is a board-certified pathologist specialized in oncologic surgical pathology and molecular genetics, with expertise in biomarker discovery, molecular diagnostics, digital pathology, AI, biobanking, and clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023